Angebote zu "Only" (4 Treffer)

Kategorien

Shops

Advances in Chronic Lymphocytic Leukemia
181,89 € *
ggf. zzgl. Versand

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatment of CLL are rooted in an in-depth understanding of the basic and translational biology of CLL. In this book, CLL experts have contributed state-of-the-art summaries of various important aspects of CLL biology and have discussed the translational implication of such findings. This book, which is directed at physicians and researchers alike, aims to educate broadly and deeply. Intentionally, the many aspects and nuances of CLL clinical care that can only really be appreciated through direct patient care are not covered here, but instead, the book presents basic aspects of CLL that underlie many of the contemporary decisions that are made in CLL research and clinical settings.We hope that this book will critically inform the community and stimulate interest in CLL, which will ultimately translate into better CLL research, prognostication and therapy, with the end goal of providing a better outlook for patients afflicted with this common leukemia.

Anbieter: Dodax
Stand: 24.01.2020
Zum Angebot
TGN1412
35,00 € *
ggf. zzgl. Versand

High Quality Content by WIKIPEDIA articles! High Quality Content by WIKIPEDIA articles! TGN1412 (also known as CD28-SuperMAB) is the working name of an immunomodulatory drug which was withdrawn from development. Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, it is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. In its first human clinical trials in March 2006, it caused catastrophic systemic organ failure in the subjects, despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, some 500 times lower than the dose found safe in animals. Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from multiple organ dysfunction, and one trial volunteer is said to show signs of developing cancer.

Anbieter: Dodax AT
Stand: 24.01.2020
Zum Angebot
TGN1412
34,00 € *
ggf. zzgl. Versand

High Quality Content by WIKIPEDIA articles! High Quality Content by WIKIPEDIA articles! TGN1412 (also known as CD28-SuperMAB) is the working name of an immunomodulatory drug which was withdrawn from development. Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, it is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. In its first human clinical trials in March 2006, it caused catastrophic systemic organ failure in the subjects, despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, some 500 times lower than the dose found safe in animals. Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from multiple organ dysfunction, and one trial volunteer is said to show signs of developing cancer.

Anbieter: Dodax
Stand: 24.01.2020
Zum Angebot

Ähnliche Suchbegriffe